Explanipedia

Functional characterization of a diet-driven hypertension-accelerated cardiovascular-kidney-metabolic syndrome KK-Ay mouse model Open

Arianne van Koppen, Romer A. González-Villalobos, Anke M. Smits, Andrea R. Nawrocki, Simon A. Hinke , et al. · 2025

AKR1A1 and Kidney Disease: Promise and Perils of the Multiverse Open

Matthew D. Breyer · 2024

Unbiased kidney-centric molecular categorization of chronic kidney disease as a step towards precision medicine Open

Anna Reznichenko, Viji Nair, Sean Eddy, Damian Fermin, Mark Tomilo , et al. · 2024

Prostacyclin Mitigates Renal Fibrosis by Activating Fibroblast Prostaglandin I2 Receptor Open

Jing Li, Yi Guan, Yunyu Xu, Yingxue Cao, Qionghong Xie , et al. · 2023

Significance Statement Renal fibrosis is a common pathologic process of progressive CKD. We have provided strong evidence that PGI 2 is an important component in the kidney injury/repairing process by reducing fibrosis and protecting renal…

Tackling AKI Open

Rajashree Rana, Matthew D. Breyer · 2023

Cardiovascular Metabolism, Janssen Research and Development LLC, Boston, Massachusetts Correspondence: Dr. Matthew D. Breyer, 4 Blackfan Circle, Boston MA 02115. Email: [email protected]. See related article, "Activation of Angiopoietin-Ti…

Mitochondrial and NAD+ metabolism predict recovery from acute kidney injury in a diverse mouse population Open

Jean‐David Morel, Maroun Bou Sleiman, Terytty Yang Li, Giacomo von Alvensleben, Alexis Bachmann , et al. · 2023

Acute kidney failure and chronic kidney disease are global health issues steadily rising in incidence and prevalence. Animal models on a single genetic background have so far failed to recapitulate the clinical presentation of human nephro…

Mapping the single-cell transcriptomic response of murine diabetic kidney disease to therapies Open

Hao Wu, Romer Gonzalez Villalobos, Xiang Yao, Dermot F. Reilly, Tao Chen , et al. · 2022

Review for "Improving Residual Risk of Renal and Cardiovascular Outcomes in Diabetic Kidney Disease: Review of Pathophysiology, Mechanisms and Evidence from Recent Trials" Open

Matthew D. Breyer · 2021

Molecular Stratification of Chronic Kidney Disease Open

Anna Reznichenko, Viji Nair, Sean Eddy, Mark Tomilo, Timothy Slidel , et al. · 2021

Current classification of chronic kidney disease (CKD) into stages based on the indirect measures of kidney functional state, estimated glomerular filtration rate and albuminuria, is agnostic to the heterogeneity of underlying etiologies, …

Erratum. Profibrotic Circulating Proteins and Risk of Early Progressive Renal Decline in Patients With Type 2 Diabetes With and Without Albuminuria. Diabetes Care 2020;43:2760–2767 Open

Katsuhito Ihara, Jan Skupień, Hiroki Kobayashi, Zaipul I. Md Dom, Jonathan M. Wilson , et al. · 2020

In Table 1 of the above-referenced article, the unit for serum matrix metalloproteinase 7 (MMP-7) …

Profibrotic Circulating Proteins and Risk of Early Progressive Renal Decline in Patients With Type 2 Diabetes With and Without Albuminuria Open

Katsuhito Ihara, Jan Skupień, Hiroki Kobayashi, Zaipul I. Md Dom, Jonathan M. Wilson , et al. · 2020

OBJECTIVE The role of fibrosis in early progressive renal decline in type 2 diabetes is unknown. Circulating WFDC2 (WAP four-disulfide core domain protein 2) and matrix metalloproteinase 7 (MMP-7; Matrilysin) are postulated to be biomarker…

Profibrotic circulating proteins and risk of early progressive renal decline in Type 2 Diabetes patients with and without albuminuria Open

Katsuhito Ihara, Jan Skupień, Hiroki Kobayashi, Zaipul I. Md Dom, Jonathan M. Wilson , et al. · 2020

OBJECTIVE: The role of fibrosis in early progressive renal decline in type 2 diabetes is unknown. Circulating WFDC2 (WAP four-disulfide core domain protein 2) and MMP-7 (Matrilysin) are postulated to be biomarkers of renal fibrosis.…

Profibrotic circulating proteins and risk of early progressive renal decline in Type 2 Diabetes patients with and without albuminuria Open

Katsuhito Ihara, Jan Skupień, Hiroki Kobayashi, Zaipul I. Md Dom, Jonathan M. Wilson , et al. · 2020

OBJECTIVE: The role of fibrosis in early progressive renal decline in type 2 diabetes is unknown. Circulating WFDC2 (WAP four-disulfide core domain protein 2) and MMP-7 (Matrilysin) are postulated to be biomarkers of renal fibrosis.…

The Use of Genomics to Drive Kidney Disease Drug Discovery and Development Open

Dermot F. Reilly, Matthew D. Breyer · 2020

As opposed to diseases such as cancer, autoimmune disease, and diabetes, identifying drugs to treat CKD has proven significantly more challenging. Over the past 2 decades, new potential therapeutic targets have been identified as genetical…

Determination of Glomerular Filtration Rate in Conscious Mice using FITC-inulin v1 Open

Zhonghua Qi, Matthew D. Breyer · 2019

Summary: This protocol describes the procedures for estimating glomerular filtration rate in conscious mice based on Fluorescein Isothiocyanate-inulin (FITC-inulin) clearance following a single bolus intravenous injection. Diabetic Complic…

Targeting VE-PTP phosphatase protects the kidney from diabetic injury Open

Isabel Anna Carota, Yael Kenig-Kozlovsky, Tuncer Onay, Rizaldy P. Scott, Benjamin R. Thomson , et al. · 2019

Diabetic nephropathy is a leading cause of end-stage kidney failure. Reduced angiopoietin-TIE2 receptor tyrosine kinase signaling in the vasculature leads to increased vascular permeability, inflammation, and endothelial cell loss and is a…

Nonselective Cyclooxygenase Inhibition Retards Cyst Progression in a Murine Model of Autosomal Dominant Polycystic Kidney Disease Open

Min Zhang, Manakan B. Srichai, Min Zhao, Jian Chen, Linda Davis , et al. · 2019

Aim: Autosomal dominant polycystic kidney disease is one of the most common genetic renal diseases. Cyclooxygenase plays an important role in epithelial cell proliferation and may contribute to the mechanisms underlying cyst formati…

Pathological and Transcriptome Changes in the ReninAAV <i>db</i>/<i>db</i> uNx Model of Advanced Diabetic Kidney Disease Exhibit Features of Human Disease Open

Shannon M. Harlan, Kathleen M. Heinz-Taheny, Jessica M. Overstreet, Matthew D. Breyer, Raymond C. Harris , et al. · 2018

The ReninAAV db/db uNx model of diabetic kidney disease (DKD) exhibits hallmarks of advanced human disease, including progressive elevations in albuminuria and serum creatinine, loss of glomerular filtration rate, and pathological changes.…

Markers of early progressive renal decline in type 2 diabetes suggest different implications for etiological studies and prognostic tests development Open

Natalia Nowak, Jan Skupień, Adam M. Smiles, Masayuki Yamanouchi, Monika A. Niewczas , et al. · 2018

Progressive Renal Disease Established by Renin-Coding Adeno-Associated Virus–Driven Hypertension in Diverse Diabetic Models Open

Shannon M. Harlan, Kathleen M. Heinz-Taheny, John M. Sullivan, Tao Wei, Hana E. Baker , et al. · 2017

Progress in research and developing therapeutics to prevent diabetic kidney disease (DKD) is limited by a lack of animal models exhibiting progressive kidney disease. Chronic hypertension, a driving factor of disease progression in human p…

A Novel Aldosterone Antagonist Limits Renal Injury in 5/6 Nephrectomy Open

Clarice Kazue Fujihara, Mark C. Kowala, Matthew D. Breyer, Claudia Ramos de Sena, Mariliza V. Rodrigues , et al. · 2017

Improved clinical trial enrollment criterion to identify patients with diabetes at risk of end-stage renal disease Open

Masayuki Yamanouchi, Jan Skupień, Monika A. Niewczas, Adam M. Smiles, Alessandro Doria , et al. · 2017

Role of TGF-alpha in the progression of diabetic kidney disease Open

Josef G. Heuer, Shannon M. Harlan, Derek Yang, Dianna L. Jaqua, Jeffrey S. Boyles , et al. · 2017

Transforming growth factor-alpha (TGFA) has been shown to play a role in experimental chronic kidney disease associated with nephron reduction, while its role in diabetic kidney disease (DKD) is unknown. We show here that intrarenal TGFA m…

Faculty Opinions recommendation of Prolactin alters blood pressure by modulating the activity of endothelial nitric oxide synthase. Open

Matthew D. Breyer · 2016

Developing Treatments for Chronic Kidney Disease in the 21st Century Open

Matthew D. Breyer, Katalin Suszták · 2016

The next generation of therapeutics for chronic kidney disease Open

Matthew D. Breyer, Katalin Suszták · 2016

Overcoming Barriers in Kidney Health—Forging a Platform for Innovation Open

Peter G. Linde, Patrick Archdeacon, Matthew D. Breyer, Tod Ibrahim, Jula K. Inrig , et al. · 2016

Innovation in kidney diseases is not commensurate with the effect of these diseases on human health and mortality or innovation in other key therapeutic areas. A primary cause of the dearth in innovation is that kidney diseases disproporti…

Aberrant bispecific antibody pharmacokinetics linked to liver sinusoidal endothelium clearance mechanism in cynomolgus monkeys Open

Amita Datta‐Mannan, Johnny E. Croy, Linda Schirtzinger, Stacy Torgerson, Matthew D. Breyer , et al. · 2016

Bispecific antibodies (BsAbs) can affect multiple disease pathways, thus these types of constructs potentially provide promising approaches to improve efficacy in complex disease indications. The specific and non-specific clearance mechani…

Prostaglandin-dependent modulation of dopaminergic neurotransmission elicits inflammation-induced aversion in mice Open

Michael Fritz, Anna M. Klawonn, Anna Nilsson, Anand Kumar Singh, Joanna Zajdel , et al. · 2015

Systemic inflammation causes malaise and general feelings of discomfort. This fundamental aspect of the sickness response reduces the quality of life for people suffering from chronic inflammatory diseases and is a nuisance during mild inf…

From bench to patient: model systems in drug discovery Open

Matthew D. Breyer, A. Thomas Look, Alessandra Cifra · 2015

Model systems, including laboratory animals, microorganisms, and cell- and tissue-based systems, are central to the discovery and development of new and better drugs for the treatment of human disease. In this issue, Disease Models & Mecha…

Matthew D. Breyer YOU? Author Swipe